Introduction {#Sec1}
============

Dilated cardiomyopathy (DCM) is characterised by ventricular chamber enlargement and impaired myocardial function and is one of the leading indications for heart transplantation \[[@CR40]\]. Besides genetic predisposition, cardiac viral infections and inflammation play a causal role in the disease process \[[@CR25], [@CR34], [@CR40]\]. Furthermore, autoimmune disorders resulting in activation of the cellular and humoral immune response have been implicated in the development of DCM \[[@CR11], [@CR29]\]. Antibodies against numerous cardiac proteins have been identified in these patients, indicating an active role in the pathogenesis by virtue of triggering the disease process or by aggravating myocardial contractile dysfunction \[[@CR28], [@CR45]\]. Furthermore, in asymptomatic relatives of patients with DCM, detection of cardiac autoantibodies predicts disease development \[[@CR8], [@CR9]\]. The pathogenic potential of autoantibodies has been proved in animal models by active immunisation as well as by transfer of antibodies directed against the corresponding epitopes, both leading to dilation and dysfunction of the ventricle \[[@CR21], [@CR27]\]. Supporting the functional role of cardiac autoantibodies in DCM, pilot studies showed that the depletion of immunoglobulins from the plasma of patients by immunoadsorption with subsequent immunoglobulin G substitution (IA/IgG) resulted in significant haemodynamic improvements, such as an increase in cardiac index, left ventricular ejection fraction (LVEF) as well as relief of symptoms \[[@CR16], [@CR17], [@CR49], [@CR50]\], and improvement of endothelial function \[[@CR6]\]. Furthermore, a decrease in activated T-cells and an increase in regulatory T-cells have been shown to be associated with haemodynamic improvement after IA/IgG, revealing a link between cellular and humoral immunity \[[@CR7]\]. Recently, cardiac autoantibodies were also detected in a subgroup of peripartum cardiomyopathy patients and may point to similarities in some of the pathophysiological processes, thus also indicating that removal of these antibodies might be a therapeutic option not only in DCM but also in peripartum cardiomyopathy \[[@CR22]\].

However, response rates to this therapeutic intervention are characterised by considerable inter-individual variability \[[@CR1], [@CR48]\]. Hence, the molecular effects triggered by therapies are of particular interest to understand the underlying mechanisms of haemodynamic improvements. Changes in therapy-related myocardial gene expression patterns have been investigated in patients with heart failure (HF) treated with left ventricular assist device (LVAD) \[[@CR23], [@CR39]\] and cardiac resynchronization therapy (CRT) \[[@CR42], [@CR53]\]. Improvement of ventricular function was associated with significant expression changes in a set of myocardial genes involved in maintenance of contractility for CRT \[[@CR53], [@CR54]\] and remodelling for LVAD \[[@CR19]\]. With respect to medical treatment, another study \[[@CR37]\] demonstrated that in patients suffering from idiopathic DCM, improvement in LVEF after treatment with beta-blockers was associated with favourable expression changes of genes encoding sarcoplasmic-reticulum calcium ATPase2α (SERCA2α) and the *α* and *β* isoforms of myosin heavy chain.

Although beneficial effects of IA/IgG have been described \[[@CR16], [@CR17], [@CR49], [@CR50]\], the potential underlying mechanisms have still to be elucidated on molecular level. Therefore, in this study comparative profiling of biopsies of DCM patients before (baseline, BL) and 6 months after (follow up, FU), IA/IgG therapy was performed and effects on gene expression and protein levels were explored to gain new information on therapy-associated molecular events.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

This pilot study comprises 33 DCM patients with LV systolic dysfunction (LVEF \<45 %) and symptoms of chronic HF according to New York Heart Association (NYHA) functional classes II and III which underwent IA/IgG in the University Hospital Greifswald between 2004 and 2008. Patients had not suffered from active infectious diseases, cancer, chronic alcoholism, postpartum cardiomyopathy, or HF due to known origins (e.g. primary valvular disease). All patients received stable oral medication for HF according to ESC guidelines \[[@CR13], [@CR47], [@CR52]\] and medication was kept stable for the duration of this study with exception of dose adjustments for diuretics (Table [1](#Tab1){ref-type="table"}, see Online Resource Supplemental Material ESM 1). Among all patients, we excluded coronary heart disease by angiography as well as acute myocarditis by endomyocardial biopsy (EMB), in accordance with Dallas criteria and immunohistological stainings \[[@CR2], [@CR12], [@CR31], [@CR38]\]. Myocardial biopsies were obtained for clinical reasons for diagnosis of DCM according to guidelines \[[@CR12], [@CR47]\] and for assessment of myocardial infections and inflammation after IA/IgG at baseline and during follow-up after 6 months (follow-up, FU). Transcriptome (*n* = 33) and proteome (subset, *n* = 23) analyses were performed from endomyocardial biopsies which were no longer needed for routine diagnostics.Table 1Baseline characteristics of DCM patientsResponder (*n* = 20)Non-responder (*n* = 13)Responder vs. non-responder\
*p* valueAge (years) ± SD^a^48 ± 1053 ± 80.145^e^Gender (♂/♀)14/612/41.000^f^LVEF (%) ± SD^a^33 ± 635 ± 70.406^e^LVIDD (mm) ± SD^a^67 ± 774 ± 70.022^e^NYHA classification II/III (*n*)10/107/61.000^e^NT-pro BNP (pg/ml) ± SD^a^1035 ± 13721047 ± 9920.428^e^Disease duration (months) ± SD^a^13 ± 1349 ± 420.003^e^Body mass index (kg/m^2^) ± SD^a^28 ± 527 ± 40.645^e^Inflammation positive (*n*)^b^1480.714^f^Fibrosis grade^c^ (*n*) 0/1/2/30/12/4/40/4/4/50.25^g^Virus genomes PVB19/PVB19+HHV6/other^d^ (*n*)4/1/154/0/9Medication (*n*/total) β-Blocker20/2013/13 ACE inhibitors and/or16/2011/13 AT1 antagonists5/205/13 Diuretics20/2013/13 Digitalis2/205/13*LVEF* left ventricular ejection fraction, *LVIDD* left ventricular internal diameter at diastole, *NYHA* New York Heart association, *NT-pro BNP* N-terminal, pro brain natriuretic peptide, *PVB19* parvovirus B19, *ACE* angiotensin converting enzyme, *AT1* angiotensin-II-receptor-subtype-1^a^Mean values with standard deviation (SD) are shown^b^Endomyocardial biopsies were considered to be inflamed if immunohistochemistry revealed focal or diffuse mononuclear infiltrates with \>14 leucocytes per mm^2^ (CD3^+^ T-lymphocytes and/or CD68^+^ macrophages) in addition to enhanced expression of HLA class II molecules \[[@CR31], [@CR38]\]^c^The amount of cardiac fibrosis in HEMBs was determined and categorised as grade 0 = no, grade 1 = mild, grade 2 = moderate, grade 3 = severe^d^Other virus types: *HHV6* human herpesvirus 6, *EBV* Epstein--Barr virus, Enteroviruses^e^Mann--Whitney test, two-tailed^f^Fisher's exact test, two-tailed^g^Chi-square test

Immunoadsorption and subsequent immunoglobulin G substitution {#Sec4}
-------------------------------------------------------------

In all patients, IA was performed on five consecutive days using protein-A columns (Immunosorba^®^, Fresenius Medical Care AG, Bad Homburg, Germany) with a treatment regime described elsewhere \[[@CR49]\]. After the final immunoadsorption session, patients received 0.5-g/kg human intravenous immunoglobulins (Venimmun, Sandoglobulin, CSL Behring, Germany, or Octagam, Octapharma, Switzerland) to restore physiological IgG plasma levels \[[@CR49]\]. Patients displaying an increase of ≥5 % in the absolute LVEF value (5 LVEF units) and ≥20 % relative to the LVEF at BL were classified as responders (R), while those not fulfilling these criteria were defined as non-responders (NR).

Echocardiography {#Sec5}
----------------

Echocardiographic parameters \[LVEF according to Simpson rule and left ventricular internal diameter at diastole (LVIDD)\] were determined by two independent physicians by two-dimensional echocardiography, performed at BL and FU 6 months after IA/IgG as described previously \[[@CR1]\].

Brain natriuretic peptide {#Sec6}
-------------------------

N-terminal pro-brain natriuretic peptide (NT-pro BNP) was determined in serum on a Siemens Dimension Vista^®^ 1500 System using an in vitro diagnostic assay based on LOCI^®^ technology (Siemens Healthcare Diagnostics Inc., Newark, USA).

Histological and immunohistological analyses and detection of viral genomes {#Sec7}
---------------------------------------------------------------------------

Five endomyocardial biopsies were fixed in 4 % buffered formaldehyde for histology and immunohistology or were fixed in RNAlater (Ambion Inc., Foster City, USA) for detection of viral genomes by nested real-time polymerase chain reaction (qRT-PCR). Histological analysis for the diagnosis of myocarditis followed the Dallas criteria complemented by immunohistology to assess inflammation as described \[[@CR31], [@CR38], [@CR41]\]. Inflammation was considered present after immunohistological detection of mononuclear infiltrates with 14 CD3^+^ T cells/and or CD68^+^ macrophages per 1 mm^2^ in the myocardium, in addition to enhanced expression of HLA class II molecules.

Fibrosis {#Sec8}
--------

The extent of myocardial fibrosis in EMB was determined from samples immediately fixed under sterile conditions in 4 % buffered formaldehyde by routine light microscopy examination using Masson\`s trichrome staining. The extent of myocardial fibrosis in EMB was defined as an index as described previously \[[@CR58]\]. The percentage area of fibrosis in the section was evaluated by dividing the sum of fibrotic areas of the section by that of the total tissue area. According to this fibrosis index, patients were classified as having no (grade 0), mild (grade 1), moderate (grade 2), or severe fibrosis (grade 3).

Transcriptome analyses {#Sec9}
----------------------

EMBs (3--4 samples) from each patient were pooled, and homogenised. From a portion of tissue powder, RNA was isolated following the manufacturer's instructions for total RNA isolation from fibrous tissues (RNeasy^®^ Micro Kit, Qiagen Inc., Valencia, USA). After purification and quality assessment, transcriptional profiling of EMBs was performed with GeneChip-Human Genome-HG U133-Plus 2.0-arrays (Affymetrix, Santa Clara, USA) as described recently \[[@CR1]\]. Expression raw data were transferred to Rosetta Resolver^®^ 7.2 (Ceiba Solutions, Seattle, USA.) for probe set extraction and normalisation. For further analyses, filtering was based on probe sets having signals above background intensity (*p* \< 0.05) in at least 80 % of one of the classes compared. In the initial phase of the study, the validity of the microarray data were confirmed by conducting qRT-PCR of selected genes in a subset of patients (9 responders, 5 non-responders) using a custom-manufactured TaqMan low density array (see Online Resource ESM 1).

Proteome analyses {#Sec10}
-----------------

For 23 patients (R: *n* = 12, NR: *n* = 11), remaining EMB tissue powders were also sufficient for proteome analysis. Protein extraction, determination of concentration, and sample preparation for mass spectrometry (MS) were performed as described earlier \[[@CR24]\]. Briefly, relative quantitation of therapy effects on protein levels was based on label-free MS analyses of tryptic peptide extracts of each patient and time point. After alignment of signals across all MS runs, signal intensities as quantitative measures were extracted and assigned to peptides and proteins by a Uniprot_SProt database search (see Online Resource ESM 1).

Statistical analyses and functional classification {#Sec11}
--------------------------------------------------

For determination of IA/IgG-related alterations on gene expression, the ratios of probe set signals at FU and BL per patient were calculated, allowing reduction of the effects of inter-individual variability at BL. Therapy effects were calculated using the rank product-based statistics method \[[@CR5]\] using 1000 permutations, generating for each probe set an average ratio and two false discovery rate (*q*) values \[[@CR51]\] for upregulation (FU/BL \>1) and downregulation (FU/BL \<1) for each group (R or NR), respectively (Fig. [1](#Fig1){ref-type="fig"}a, b). The same algorithm was applied to compare ratios of responders and non-responders (R FU/BL vs. NR FU/BL) (Fig. [1](#Fig1){ref-type="fig"}c). Probe sets with significant (*q* \< 0.05) upregulation (R FU/BL \> NR FU/BL) or downregulation (R FU/BL \< NR FU/BL) were considered differentially affected by IA/IgG and selected for further analysis. Gene expression data were also analysed with adjustment for inflammation and fibrosis (see Online Resource ESM 1). IA/IgG-associated changes on protein level were calculated as described above except no multiple test correction was applied due to the lower number of molecules in the analyses and a fold change filter (FC) of 1.3 was used.Fig. 1Schematic overview of analyses. Exemplarily, an altered gene/protein level per patient---as indicated by follow-up (FU) vs. baseline (BL) ratios per patient (*bar*) for **a** responders (R) and **b** non-responders (NR), was shown. To define differences between subgroups, ratios of responders and non-responders were compared with each other (**c**)

The descriptive statistics of clinical parameters are expressed as mean with standard deviation (SD). Mann--Whitney test, Fisher's exact test, Wilcoxon-signed rank test, and Pearson's Chi-square test were used for appropriate comparisons.

Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, USA; <http://www.ingenuity.com>) was used for functional assignments of differentially expressed genes and altered proteins. Expression data have been submitted to the NCBI gene-expression and hybridization-array data repository (GEO).

Results {#Sec12}
=======

Baseline characteristics of patients {#Sec13}
------------------------------------

Clinical BL characteristics of all patients are summarised in Table [1](#Tab1){ref-type="table"}. LVEF and NYHA classes showed no significant difference at BL between responders and non-responders, but patient groups significantly differed in LVIDD (*p* = 0.022) and disease duration (*p* \< 0.003). Serum levels of the heart failure marker NT-pro BNP as well as inflammation, virus detection, and fibrosis findings from EMBs of responders and non-responders did not differ significantly between both groups.

Clinical findings and haemodynamic changes after immunoadsorption and subsequent immunoglobulin G substitution {#Sec14}
--------------------------------------------------------------------------------------------------------------

IA/IgG treatment was tolerated well by all 33 patients, and no serious events occurred. Immunoglobulin G levels were reduced by 94.7 ± 2 % 5 days after IA, with no significant difference in subgroups (responders 95.4 ± 1 %, non-responders 94.1 ± 3 %). In the responder group, LVEF increased from 33 ± 6 % at BL to 47 ± 6 % after 6 months (*p* \< 0.001). Simultaneously, LVIDD decreased from 67 ± 7 to 60 ± 7 mm (*p* \< 0.001), and NYHA class improved from NYHA class III/II to II/I (*p* = 0.021). In contrast, LVEF (35 ± 7 % at BL to 36 ± 8 % at FU) and LVIDD (74 ± 7 mm at BL to 73 ± 9 mm at FU) remained almost unchanged in non-responders (Table [2](#Tab2){ref-type="table"}). Moreover, the number of patients with myocardial inflammation decreased significantly among the responders from BL (*n* = 14) to FU (*n* = 6, *p* = 0.026), and serum NT-pro BNP level was significantly decreased (1035 to 463 pg/ml, *p* \< 0.004) in this group 6 months after treatment compared with BL (Fig. [2](#Fig2){ref-type="fig"}). In non-responders, these parameters did not change significantly. The grade of fibrosis in Masson Trichrome stained EMB tissue sections as evaluated by light microscopy did not change in any of the two groups after IA/IgG (Table [2](#Tab2){ref-type="table"}). Individual patient data are shown in Fig. [2](#Fig2){ref-type="fig"}.Table 2Longitudinal characteristics of IA/IgG populationResponder (*n* = 20)Non-responder (*n* = 13)BLFU*p* ^d^BLFU*p* ^d^Subgroup specific differences after IA/IgG LVEF (%) ± SD^a^33 ± 647 ± 6\<0.00135 ± 736 ± 80.344 LVIDD (mm) ± SD^a^67 ± 760 ± 7\<0.00174 ± 773 ± 90.586 NT-pro BNP pg/ml ± SD^a^1035 ± 1372463 ± 923\<0.0041047 ± 9921196 ± 12110.839 Inflammation positive (*n*)^b^1460.026^e^891.000^e^ NYHA I/II/III/IV (*n*)0/10/10/06/9/5/00.021^f^0/7/6/02/8/3/00.216^f^ Fibrosis grade^c^ 0/1/2/3 (*n*)0/12/4/40/12/5/30.838^f^0/4/4/50/3/5/50.806^f^Differences between subgroups after IA/IgG ΔLVEF (%) ± SD^a^13 ± 61 ± 4\<0.001^g^ ΔLVIDD (mm) ± SD^a^−7 ± 50 ± 3\<0.001^g^ ΔNT-pro BNP pg/ml ± SD^a^−572 ± 1099148 ± 8130.172^g^*LVEF* left ventricular ejection fraction, *LVIDD* left ventricular internal diameter at diastole, *NYHA* New York Heart Association^a^Mean values with standard deviation (SD) are shown^b^Myocardial biopsies were considered to be inflamed if immunohistochemistry revealed focal or diffuse mononuclear infiltrates with \>14 leucocytes per mm^2^ (CD3^+^ T-lymphocytes and/or CD68^+^ macrophages) in addition to enhanced expression of HLA class II molecules \[[@CR31], [@CR38]\]^c^The amount of cardiac fibrosis in HEMBs was determined and categorised as grade 0 = no, grade 1 = mild, grade 2 = moderate, grade 3 = severe^d^ *p* value baseline (BL) vs. follow up (FU) of responders and non-responders is based on Wilcoxon-signed rank test^e^Fisher's exact test, two-tailed^f^Chi-square test^g^ *p* value ΔLVEF, ΔLVIDD, ΔNT-pro BNP \[absolute change of LVEF, LVIDD or NT-pro BNP (FU-BL)\] of responders vs. non-responders is based on Mann--Whitney test, two-tailed Fig. 2Individual changes in **a** LVEF, **b** LVIDD, **c** NT-pro BNP plasma levels, **d** inflammation as indicated by infiltrated leucocytes (CD3^+^ T-lymphocytes and/or CD68^+^ macrophages) \[(**a**--**d**) *p* value derived by Wilcoxon-signed rank test, for both subgroups)\], and **e** fibrosis grade after IA/IgG (Chi-square test, for both subgroups, *ns*. not significant)

Changes in myocardial gene expression and protein levels in responders and non-responders after IA/IgG {#Sec15}
------------------------------------------------------------------------------------------------------

Responders and non-responders were analysed separately (Fig. [1](#Fig1){ref-type="fig"}a, b) to elucidate gene expression changes after IA/IgG. In general, more genes were altered in responders (244 genes, mean of individual FU over BL ratios FC ≥ \|1.2\|, *q* \< 0.05) after IA/IgG therapy than in non-responders (129 genes, see Online Resource Supplemental Tables ESM 2, ESM 3). Functional assignment of genes altered significantly in expression levels at FU compared with BL in the respective subgroup revealed largely different categories or a different level of alterations for responders and non-responders (Fig. [3](#Fig3){ref-type="fig"}a, c). In responders, preferentially genes of the categories *skeletal and muscular system development and function* (42 genes) and *connective tissue development and function* (41 genes) were altered after therapy. For the majority of the respective genes, lower expression was found in responders after IA/IgG compared with BL (Fig. [3](#Fig3){ref-type="fig"}b, Online Resource Supplemental Table ESM 4).Fig. 3Altered gene expression of HF markers in responder (R) and non-responder (NR) before (BL) and after (FU) IA/IgG therapy. Mean signal intensities and standard deviation were depicted for POSTN---periostin, ACE2---angiotensin converting enzyme, CTGF---connective tissue growth factor, NPPA---atrial natriuretic factor and NPPB---brain natriuretic peptide for responders (R, *n* = 20) and non-responders (NR, *n* = 13) (rank product test, *q* FDR-value, rank product test, *ns.* not significant)

Significantly lower gene expression was observed for periostin (POSTN), angiotensin converting enzyme 2 (ACE2), and the connective tissue growth factor (CTGF) at FU compared with BL in responders, whereas, in non-responders, the expression of these genes remained unchanged or even increased (Fig. [4](#Fig4){ref-type="fig"}). Transcripts of natriuretic peptides A (NPPA) and B (NPPB) showed the same declining trend in responders (Fig. [4](#Fig4){ref-type="fig"}), indicating a slightly better status after therapy compared with non-responders.Fig. 4Functional assignment of genes regulated in responders (R) and non-responders (NR) after IA/IgG (\|1.2\|, *q* \< 0.05, responder 244 genes, and non-responders 129 genes). Top 3 enriched categories of *physiological system development and function* and direction of regulated genes in responders (**a**, **b**) and non-responders (**c**, **d**) are displayed. Data of both patient groups are shown comparatively (*white bars* R; *black* NR). Significance (−log BH *p* value) of the association, which is dependent on the number of genes in the class, was Benjamini--Hochberg (BH) corrected as assigned by Ingenuity Pathways Analysis

qRT-PCR analysis for a subset of patients revealed the same significant decrease for both natriuretic peptides ANP, BNP, and ACE2 in responders (*n* = 9), but not in non-responders (*n* = 5) (Online Resource ESM 5 Supplemental Fig. S1), supporting the microarray data (Fig. [4](#Fig4){ref-type="fig"}). Microarray data (see Online Resource Supplemental Tables ESM 2, ESM 3) were also confirmed for natriuretic peptide receptor 3 (NPR3) and CORIN, whereas data for periostin (POSTN) were not confirmed by qRT-PCR in the smaller subset.

Further inverse regulation upon IA/IgG in responders and non-responders was observed for additional six genes, including chemokine (C-X-C motif) ligand 11 (CXCL11), golgi glycoprotein 1 (GLG1), iroquois homeobox 1 (IRX1), mitochondrial ribosomal protein S18C (MRPS18C), peripheral myelin protein 2 (PMP2), and hyaluronan and proteoglycan link protein 1 (HAPLN1) (see Online Resource ESM 5 Supplemental Fig. S2).

Of the genes affected in expression level by IA/IgG (R: 244 genes, NR: 129 genes), 10 genes including CORIN (see Online Resource ESM 5 Supplemental Fig. S2) displayed a conserved effect in responders and non-responders.

By functional assignment of genes altered significantly in expression levels at FU compared with BL in non-responders, the highest significance was observed for *haematological system development and function* (38 genes), *immune cell trafficking* (28 genes), and *cardiovascular system development and function* (25 genes) categories which were also affected but to a lesser degree in responders (Fig. [3](#Fig3){ref-type="fig"}c, Online Resource Supplemental Table ESM 6). Since, in non-responders, no changes in LVEF were observed, these alterations do not seem to be associated with improvement of heart function. In total, IA/IgG-associated gene expression changes pointed to a rather diverse pattern than an alteration of a defined pathway. Since inflammation and fibrosis are known parameters associated with DCM progression and affected by IA/IgG (Table [2](#Tab2){ref-type="table"}), data were adjusted for these cofactors to screen for effects independent of these two cofactors. We observed a stronger influence of the adjustment for inflammation and fibrosis on the data of responders compared with non-responders (see Online Resource ESM 5 Supplemental Fig. S3). The adjustment for the factors inflammation or fibrosis revealed a decrease in the number of significantly regulated genes and the corresponding *p* values in responders but triggered only marginal changes in non-responders. Functional categorization of the genes remaining after adjustment (see Online Resource ESM 7 and ESM 8) did not reveal hints for other pathways targeted by IA/IgG in any of the two patient subgroups.

Alterations on protein level were only minor in responders (16 proteins) and non-responders (43 proteins, see Online Resource ESM 9 and ESM 10, respectively). Notably, in responders, an increase in prostaglandin D2 synthase abundance was observed and confirmed, thereby, the microarray data.

Subgroup specific differences in ECM remodelling after IA/IgG {#Sec16}
-------------------------------------------------------------

To gain a better insight into the molecular alterations triggered by IA/IgG in the two patient subgroups, we compared the magnitude of the gene expression/protein abundance changes after IA/IgG of responders and non-responders (Fig. [1](#Fig1){ref-type="fig"}c).

Comparison of FU over BL ratios of both subgroups revealed significantly different alterations upon IA/IgG in 320 genes (*q* \< 0.05, FC ≥ \|1.2\|, see Online Resource Supplemental Table ESM 11). Functional classification of those genes highlighted the following categories of molecular and cellular function: *cellular assembly and organisation* (25 genes); *function and maintenance* (33genes); and *cellular movement* (77 genes) (see Online Resource Supplemental Table ESM 12). Among the canonical pathways, the difference was most pronounced for genes associated with fibrosis (Fig. [5](#Fig5){ref-type="fig"}a).Fig. 5Differentially affected canonical pathways after IA/IgG in responders and non-responders. Functional assignment of differentially affected genes (**a**) and proteins (**b**) points to a different response of subgroups in fibrotic pathway. Significance (−log *p* value) of the association, which is dependent on the number of genes/proteins in the class, as assigned by ingenuity pathways analysis

Responders displayed significantly lower expression after therapy compared with BL (ratio FU/BL \< 1), whereas, in non-responders, expression was higher after therapy compared with BL (ratio FU/BL \> 1) for fibrosis-associated genes, such as collagen 1A2 (COL1A2), collagen 3A1 (COL3A1), biglycan (BGN), and connective tissue growth factor (CTGF) (Fig. [6](#Fig6){ref-type="fig"}), indicating lower expression of pro-fibrotic genes after IA/IgG in responders. These findings are in line with the appearance of *cellular assembly and organisation* as the most significant biological function highlighting additional genes encoding extracellular matrix proteins (e.g. versican, dermatopondin, collagen 5A2) and indicating differences among subgroups in extracellular matrix remodelling processes after IA/IgG.Fig. 6Fibrosis-associated genes of responder and non-responder groups. Geometric mean of ratio intensity data (FU/BL) and standard deviation (SD) were calculated for the subgroups responder (R) and non-responder (NR) and displayed for collagen 3A1 (COL3A1), collagen 1A2 (COL1A2), biglycan (BGN), and connective tissue growth factor (CTGF) (rank product test, *q* FDR value)

Significant differences in protein ratios (FU/BL) between responders and non-responders were observed for 57 proteins (FC ≥ \|1.3\|, *p* \< 0.001) (see Online Resource Supplemental Table ESM 13). Functional assignment of those proteins revealed enrichment for, e.g. *integrin linked kinase* (*ILK*) *signalling*, *calcium signalling*, *actin cytoskeleton signalling* as well as *fibrosis* (Fig. [5](#Fig5){ref-type="fig"}b, see Online Resource Supplemental Table ESM 14). In concordance with the gene expression results, significantly lower ratios were observed for fibrosis-associated proteins in responders than in non-responders (R FU/BL \< NR FU/BL). Among them, collagen 1A1, lumican, prolargin, and biglycan were found, indicating strong IA/IgG-dependent differences in regulation of extracellular matrix components in the two subgroups (Fig. [7](#Fig7){ref-type="fig"}, Online Resource Supplemental Table ESM 13). Differences were also observed for cAMP-dependent protein kinase A, catalytic subunit beta, and myosin regulatory light chain 7 (R FU/BL \> NR FU/BL) but not myosin heavy chain 6 or 7. Significantly lower ratios (R FU/BL \< NR FU/BL) were observed in responders for myosin heavy chain 11 and myosin regulatory light chain 9. Furthermore, proteome data confirmed transcriptome data for periostin.Fig. 7Selected proteins in the responder and non-responder groups. Geometric mean of ratio intensity data (FU/BL) and standard deviation of collagen 1A1, lumican, periostin, prolargin, biglycan, and myosin light chain 7 were compared and displayed for the subgroups responder (R, *n* = 12) and non-responder (NR, *n* = 11) (rank product test, R FU/BL vs. NR FU/BL, *q* FDR value)

IA/IgG-associated changes in transforming growth factor beta signalling in responders {#Sec17}
-------------------------------------------------------------------------------------

Based on the observed IA/IgG-associated changes in gene expression and protein levels in the EMBs of responders and non-responders as well as the differences between the two subgroups at FU, an analysis with the Ingenuity Pathway Analysis suite predicted a lower expression/activity of transforming growth factor beta in responders than in non-responders (see Online Resource ESM 5 Supplemental Fig. S4). In line with this prediction, latent transforming growth factor binding protein 2 displayed decreased levels in responders 6 months after IA/IgG, whereas no significant change in levels was observed in non-responders. Table [3](#Tab3){ref-type="table"} summarises the different changes after IA/IgG on transforming growth factor dependent molecules in responders and non-responders.Table 3Genes and proteins with significant differentially alterations upon IA/IgG which leads to the prediction of an more active TGFß-signalling in non-responders (NR) than in responders (R) after therapyGenesGene/protein nameProbe set IDDifference in IA/IgG effect NR vs RUniprot IDmRNAProteinLOXLysyl oxidase215446_s\_at1.56n.d.CTGFConnective tissue growth factor209101_at1.54n.d.**BGNBiglycan213905_x\_atP218101.512.02**LTBP2Latent transforming growth factor beta binding protein 2204682_at1.49n.d.**POSTNPeriostin210809_s\_atQ150631.492.12**COL3A1Collagen, type III, alpha 1211161_s\_at1.43n.d.LOXL1Lysyl oxidase-like 1203570_at1.41n.d.**COL1A2collagen, type I, alpha 2202404_s\_atP081231.391.71**F2RCoagulation factor II (thrombin) receptor203989_x\_at1.36n.d.INHBAInhibin, beta A227140_at1.32n.d.NOX4NADPH oxidase 4219773_at1.31n.d.RASL11BRAS-like, family 11, member B219142_at1.31n.d.**COL1A1Collagen, type I, alpha 11556499_s\_atP024521.302.13**TAGLNTransgelin205547_s\_atQ019951.301.29SPP1Secreted phosphoprotein 1209875_s\_at1.26n.d.VIMVimentin201426_s\_atP08670−*1.10*1.43NPPANatriuretic peptides A209957_s\_atP01160*1.371.36*MFAP4Microfibril-associated glycoprotein 4P55083n.d.1.51FN1Fibronectin211719_x\_atP02751*1.22*1.32FBN1Fibrillin-1202766_s\_atP35555*1.11*n.d.FBLN5Fibulin-5Q9UBX5n.d.1.85Bold: significant in proteome and transcriptome approach, italics: not significant*NR* non-responder, *R* responder, *n.d.* not detected

Discussion {#Sec18}
==========

Immunoadsorption with subsequent IgG substitution represents a therapeutic approach for the treatment of patients with DCM. Several studies on IA/IgG showed beneficial effects on myocardial and endothelial function \[[@CR7], [@CR16], [@CR32], [@CR49], [@CR50]\]. However, response to this therapeutic intervention shows wide inter-individual variability \[[@CR1]\]. The molecular mechanisms that explain the variability in response to therapy of DCM patients still remain to be elucidated. This is the first report addressing IA/IgG-related changes in the myocardium at the molecular level by performing transcriptomic and proteomic profiling.

Changes in DCM-related myocardial gene expression in responders and non-responders upon IA/IgG therapy {#Sec19}
------------------------------------------------------------------------------------------------------

A recent profiling of myocardial gene expression patterns of responders and non-responders at baseline before IA/IgG in comparison with control individuals revealed differential expression between responders and non-responders for genes assigned to oxidative phosphorylation, mitochondrial dysfunction, hypertrophy, and ubiquitin--proteasome pathway \[[@CR1]\]. Surprisingly, according to this study, none of these pathways was affected by IA/IgG, neither in responders nor in non-responders (see Online Resource Supplemental Material ESM 15, ESM 5 Supplemental Fig. S5). Only a few genes described as altered in DCM previously \[[@CR1]\] were inversely affected in expression after IA/IgG in responders (seven genes: LTBP2, RGS4, SERPINE2, SH3GL2, TAGLN, FAM124A, MRO) and non-responders (six genes: ACTG2, MRO, IDS, MTHFD2L, CREB5, GLG1), respectively (see Online Resource Supplemental ESM 15 and Supplemental Tables ESM 2 and ESM 3). Similar observations were made on the proteome level: IA/IgG-related alterations overlapped only to a minor extent with the DCM-associated changes in protein levels reported previously \[[@CR24]\] (see Online Resource Supplemental Tables ESM 9 and ESM 10). Hence, the molecular processes influenced by DCM and IA/IgG seem to differ substantially.

In general, the magnitude of IA/IgG-associated alterations in mRNA levels of responders (244 genes) was similar to that of disease-associated alterations previously recorded (208 genes \[[@CR1]\]. However, since the disease- and therapy-associated alterations barely overlapped, the IA/IgG-related changes might not be causative for the functional and clinical improvement, but might rather reflect secondary effects. These findings are in line with observations by Margulies et al. who studied the molecular changes in human pre- and post-LVAD samples \[[@CR39]\]. Only a minor proportion of HF-associated alterations exhibited normalisation indicating morphological and functional improvements without reversing pathological expression patterns \[[@CR39]\]. Margulies et al. hypothesised that many HF-associated changes in transcript levels have only a limited role in regulation of cardiac structure and function and may represent epiphenomena \[[@CR39]\]. In line with this observation, global heart failure-related gene expression patterns were largely unaffected by cardiac resynchronization therapy (CRT) \[[@CR4]\]. However, dyssynchrony-induced expression changes were reversed in a region-specific manner for transcripts and proteins with metabolic and cell signalling function by CRT \[[@CR4]\].

Myocardial molecular changes in responders and non-responders upon IA/IgG therapy {#Sec20}
---------------------------------------------------------------------------------

Improvement of heart function in the responder group after IA/IgG was associated with a reduced LVIDD, a decrease in inflammation as determined by the number of infiltrating immune cells, and a decreased serum NT-pro BNP level. NT-pro BNP is stimulated by pathophysiological stressors, such as hypoxia, biomechanical stretch or ventricular hypertrophy \[[@CR56]\], and is accepted as a biomarker reflecting the severity of HF \[[@CR46]\]. The significant downregulation of NPPA and NPPB after IA/IgG that was found in responders exclusively might thus reflect differences in myocardial function of the patient subgroups. CORIN, the gene encoding atrial natriuretic peptide-converting enzyme, which catalyses the conversion of NT-pro ANP and to a lesser extent also NT-pro BNP \[[@CR14]\], was found at significant higher levels after IA/IgG in responders compared with BL. Furthermore, CORIN was expressed at higher levels after IA/IgG in responders compared with non-responders which might explain in part the reduced NT-pro BNP levels in this patient subgroup. In a murine DCM model, overexpression of CORIN was associated with improved cardiac function, reduced myocardial fibrosis, and prolonged survival \[[@CR20]\]. These observed beneficial effects of increased corin levels might be secondary to the effects of processed natriuretic peptides ANP and BNP. Besides regulation of intravascular blood volume and vascular tone, BNP and ANP also display cardioprotective effects by inhibition of inflammation and cardiac fibrosis, and thus, each of these mechanisms may also influence the progression of dilated cardiomyopathy \[[@CR43], [@CR55]\]. Especially, BNP is assumed to act locally as an anti-fibrotic factor by inhibiting collagen synthesis and proliferation of cardiac fibroblasts which, in turn, inhibits cardiac fibrosis \[[@CR20], [@CR43], [@CR44]\].

In our study, major alterations were found for extracellular matrix components which were predominantly pronounced in responders and fit well with the observation of a decreased left ventricular diameter indicating myocardial recovery. After IA/IgG, responders showed lower expression of different collagens (Fig. [6](#Fig6){ref-type="fig"}) compared with non-responders. Furthermore, in non-responders, lumican levels increased but not in responders (Fig. [7](#Fig7){ref-type="fig"}). Increased expression of lumican in the myocardium of patients with HF was recently reported, and a pathophysiological role affecting extracellular matrix (ECM) was suggested by initiating increased ECM collagen cross-linking and cardiac fibrosis \[[@CR15]\]. Furthermore, lower expression in responders than in non-responders after IA/IgG was found for the heart failure marker and ECM component periostin which is associated with myocardial fibrosis in human failing hearts \[[@CR57]\]. Animal experiments already revealed that inhibition of periostin gene expression resulted in a significant increase in survival rate accompanied by an improvement of LV function \[[@CR30]\]. In addition, responders showed a downregulation of the fibrosis-associated gene CTGF \[[@CR35]\], which is induced by growth factor TGF-β \[[@CR10]\]. Expression of TGF-β-dependent genes and levels of proteins, such as fibronectin (FN1) and different collagens (COL1A1 and COL1A2) \[[@CR10]\], were significantly different (Table [3](#Tab3){ref-type="table"}) in responders and non-responders after IA/IgG. Although no direct association of IA/IgG with TGF-ß mRNA and protein levels was detected, a higher TGF-ß activity in non-responders was predicted independently for proteome as well as transcriptome data. The difference in the molecular remodelling might be caused by a higher expression of latent transforming growth factor binding protein 2 (LTBP2) in non-responders, which was recently described as a new biomarker for heart failure \[[@CR3]\]. LTBP2 is part of the latent TGF-ß1 complex. As a further component of the extracellular matrix, LTBP2 seems to contribute directly to myocardial remodelling and fibrosis, which was more pronounced in non-responders than in responders 6 months after IA/IgG. Improved LV function after LVAD implant therapy was also associated with reduced transcript levels of pro-fibrotic genes COL1A1 and COL3A1 as well as fibronectin 1 \[[@CR18]\]. For extracellular matrix components, similar results were obtained in an LVAD implant study with patients suffering from cardiomyopathy. However, despite reduced levels of mRNA for TGF-ß1, CTGF, COL1A1, and COL3A1, only a modest reduction in tissue fibrosis was monitored between pre- and post-LVAD tissue samples by mechanical unloading \[[@CR33]\]. Intriguingly, continuous-flow LVAD support is associated with increased myocardial fibrosis as well as circulating pro-fibrotic markers \[[@CR36]\] and might emphasise the need of an earlier LVAD implantation for improvement in advanced HF. As a result of CRT---a therapeutic intervention against the loss of ventricular heart function in DCM patients---upregulation of contractility regulating genes, such as sarcoplasmatic reticulum calcium ATPase 2α (ATP2A2), phospholamban (PLN), beta-1-adrenoreceptor (ADRB1), and apelin (APL), was reported \[[@CR26], [@CR42], [@CR53]\]. However, these genes were not found to be changed after IA/IgG irrespective of the responder status in our study (see Online Resource ESM 5 Supplemental Fig. S6). Our transcriptome and proteome data indicate differences in ECM remodelling instead of increase in expression or level of contractile proteins after IA/IgG.

Study limitation {#Sec21}
================

A control group of DCM patients which did not receive IA/IgG but for which FU biopsy was performed after 6 months was not available. Therefore, at least in theory, the changes in myocardial gene expression and proteome observed in responders may reflect differences in the natural course of disease rather than the effect of therapeutic intervention with IA/IgG. In this context, responders and non-responders display differences in disease duration. Therefore, it may be argued that differences in gene regulation after IA/IgG found in responders and non-responders are related, at least in part, to the significant differences in disease duration with better myocardial recovery in patients exhibiting shorter disease duration. Compared with non-responders, the less advanced disease process in responders is also mirrored by significantly lower LVIDD at baseline. However, we consider it unlikely that the molecular differences observed are primarily attributable to differences in disease stages, because the same molecular differences between responders and non-responders are also seen in patients of both subgroups having similar disease duration (see Online Resource ESM 5 Supplemental Fig. S7). The total number of subjects available for the study as well as for the validation of results by qRT-PCR approach limits the power of the analyses. However, the study is based on paired comparisons of samples of the same patients, which greatly reduces the overall variability. The gene expression and protein analyses data overlap only to minor extent (see Online Resource ESM 5 Supplemental Fig. S8), but the results point to a common result---a difference in the myocardial remodelling and fibrosis. One reason is the lower coverage of the proteome by the LC--MS/MS analysis in comparison with the transcriptome accessible by microarray analyses. Furthermore, it is known that mRNA and protein levels do not essentially correlate, because the latter one depends, e.g. on mRNA stability, translation rate, protein degradation rate, and other factors.

Conclusion {#Sec22}
==========

This is the first study relating IA/IgG therapy characteristics with comprehensive global molecular changes in myocardial biopsies of DCM patients. Improvement of LVEF, LVIDD, and NYHA classes, and inflammation status were accompanied by reduced serum natriuretic peptide levels and lower expression of TGF-ß dependent extracellular matrix components and fibrosis markers in responders. A few single molecules clearly show different expression pattern/protein levels in the patient subgroups, e.g. LTPB2, CORIN, periostin, and transgelin, but the importance or even causative role of those molecules in the functional recovery process in responders has to be shown in the future studies. IA/IgG did not normalise DCM-associated expression profiles reported earlier \[[@CR1], [@CR24]\]. In contrast to other studies on therapeutic intervention effects in DCM patients \[[@CR26], [@CR42], [@CR53]\], normalised neurohormonal activity and beneficial LV remodelling in the responder group were not accompanied by a positive effect on molecules of the Ca2^+^-handling. A placebo-controlled multicentre study on IA/IgG therapy is still in progress (NCT00558584). Analysis of this data will show if IA/IgG is a potential treatment option for a subset of patients suffering from dilated cardiomyopathy, and material of this patient cohort might be useful to verify the findings of this pilot study.
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